Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Core Viewpoint - Quoin Pharmaceuticals Ltd. has launched the "NETHERTON NOW" campaign to raise awareness about Netherton Syndrome, a genetic disease with significant misdiagnosis rates and high mortality risk among infants [1][4]. Company Overview - Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a commitment to addressing unmet medical needs [9]. - The company is developing therapeutic products, including QRX003, aimed at treating Netherton Syndrome and other rare conditions [9]. Netherton Syndrome Insights - Netherton Syndrome is characterized by severe skin issues, including excess skin shedding, red scaly skin, and a high risk of dehydration and infections [2][7]. - The condition is caused by a mutation in the SPINK5 gene, leading to significant physical, emotional, and social challenges for patients and their families [6][4]. Clinical Development - Quoin is conducting four ongoing clinical studies to evaluate the safety and efficacy of QRX003 in patients with Netherton Syndrome [3]. - Recent clinical data has shown promising results for QRX003, with photographic evidence demonstrating significant skin improvement after 12 weeks of treatment [3]. - A "whole body" clinical study has been approved by the U.S. Food and Drug Administration and will be led by Dr. Amy Paller at Northwestern University [3]. Campaign Objectives - The "NETHERTON NOW" campaign aims to increase public awareness, foster advocacy, and provide educational resources about Netherton Syndrome [4][5]. - The campaign also seeks to address the long diagnostic delays faced by patients and the lack of approved treatments [4]. Product Information - QRX003 is a topical lotion designed to improve skin barrier function and normalize skin shedding, addressing the core issues of Netherton Syndrome [8]. - The product utilizes proprietary delivery technology to act as a serine protease inhibitor, compensating for the absence of the LEKTI protein in affected patients [8].